Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Organisation › Details

Zedira GmbH

The Darmstadt-based biotech company has a focus on celiac disease and other transglutaminase-linked conditions in the arena of autoimmunity, fibrotic disease and coagulation. The company develops, produces and markets specialist reagents and kits for research and development as well as for clinical diagnostics. Zedira is also establishing a pipeline of drug candidates adapted to specific indications based on its patented family of low-molecular transglutaminase blockers. ZED1227 is the first direct acting transglutaminase inhibitor entering clinical development. The company is actively progressing follow-on candidate molecules informed by the know-how gained with development of ZED1227 and aims at new approaches in thrombosis prophylaxis. Zedira is a portfolio company of the German High-Tech Gründerfonds. *

 

Period Start 2007-01-01 established
  Predecessor N-Zyme Biotec GmbH
Products Industry ZED1227 (Zedira / Dr Falk Pharma)
  Industry 2 transglutaminase
Persons Person Hils, Martin (Zedira 201106 CEO + co-founder before N-Zyme Biotec)
  Person 2 Pasternack, Ralf (Zedira 201106 Managing Director + co-founder before N-Zyme Biotec 200506 Managing Director)
     
Region Region Darmstadt
  Country Germany
  Street 83 Roesslerstr.
  City 64293 Darmstadt
  Tel +49-6151-3251-00
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2012-06-22)
  Currency EUR
  Annual sales 500,000 (sales (annual, about) 2011-12-31)
     
    * Document for �About Section�: Zedira GmbH. (3/2/15). "Press Release: Dr. Falk Pharma and Zedira Enter Phase I Clinical Trials for a Celiac Disease Drug". Freiburg & Darmstadt.
     
   
Record changed: 2018-04-29

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Zedira GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top